|
1
|
Ren J, Zhang H, Wang J, Xu Y, Zhao L and
Yuan Q: Transcriptome analysis of adipocytokines and their-related
LncRNAs in lung adenocarcinoma revealing the association with
prognosis, immune infiltration, and metabolic characteristics.
Adipocyte. 11:250–265. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleczko EK, Kwak JW, Schenk EL and
Nemenoff RA: Targeting the complement pathway as a therapeutic
strategy in lung cancer. Front Immunol. 10:9542019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schrader M and Laberke HG: Differential
diagnosis of verrucous carcinoma in the oral cavity and larynx. J
Laryngol Otol. 102:700–703. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng TY, Cramb SM, Baade PD, Youlden DR,
Nwogu C and Reid ME: The international epidemiology of lung cancer:
Latest trends, disparities, and tumor characteristics. J Thorac
Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kris MG, Gaspar LE, Chaft JE, Kennedy EB,
Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, et al:
Adjuvant systemic therapy and adjuvant radiation therapy for stage
I to IIIA completely resected non-small-cell lung cancers: American
society of clinical oncology/cancer care ontario clinical practice
guideline update. J Clin Oncol. 35:2960–2974. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reck M, Remon J and Hellmann MD:
First-line immunotherapy for non-small-cell lung cancer. J Clin
Oncol. 40:586–597. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Quail DF and Joyce JA: The
microenvironmental landscape of brain tumors. Cancer Cell.
31:326–341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo W, Zeng Z, Jin Y, Yang L, Fan T, Wang
Z, Pan Y, Yang Y, Yao M, Li Y, et al: Distinct immune
microenvironment of lung adenocarcinoma in never-smokers from
smokers. Cell Rep Med. 4:1010782023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lambrechts D, Wauters E, Boeckx B, Aibar
S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den
Eynde K, et al: Phenotype molding of stromal cells in the lung
tumor microenvironment. Nat Med. 24:1277–1289. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo X, Zhang Y, Zheng L, Zheng C, Song J,
Zhang Q, Kang B, Liu Z, Jin L, Xing R, et al: Global
characterization of T cells in non-small-cell lung cancer by
single-cell sequencing. Nat Med. 24:978–985. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu F, Fan J, He Y, Xiong A, Yu J, Li Y,
Zhang Y, Zhao W, Zhou F, Li W, et al: Single-cell profiling of
tumor heterogeneity and the microenvironment in advanced non-small
cell lung cancer. Nat Commun. 12:25402021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maitz K, Valadez-Cosmes P, Raftopoulou S,
Kindler O, Kienzl M, Bolouri H, Houghton AM, Schicho R, Heinemann A
and Kargl J: Altered treg infiltration after discoidin domain
receptor 1 (DDR1) inhibition and knockout promotes tumor growth in
lung adenocarcinoma. Cancers (Basel). 15:57672023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang J, Bi G, Shan G, Jin X, Bian Y and
Wang Q: Tumor-associated regulatory T cells in non-small-cell lung
cancer: Current advances and future perspectives. J Immunol Res.
2022:43553862022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi
JW, Lee JI, Suh YL, Ku BM, Eum HH, et al: Single-cell RNA
sequencing demonstrates the molecular and cellular reprogramming of
metastatic lung adenocarcinoma. Nat Commun. 11:22852020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wilkerson MD, Yin X, Walter V, Zhao N,
Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne
LB, et al: Differential pathogenesis of lung adenocarcinoma
subtypes involving sequence mutations, copy number, chromosomal
instability, and methylation. PLoS One. 7:e365302012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schabath MB, Welsh EA, Fulp WJ, Chen L,
Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et
al: Differential association of STK11 and TP53 with KRAS
mutation-associated gene expression, proliferation and immune
surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rody A, Holtrich U, Pusztai L, Liedtke C,
Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et
al: T-cell metagene predicts a favorable prognosis in estrogen
receptor-negative and HER2-positive breast cancers. Breast Cancer
Res. 11:R152009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thorsson V, Gibbs DL, Brown SD, Wolf D,
Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy
JA, et al: The immune landscape of cancer. Immunity. 51:411–412.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Erfani N, Mehrabadi SM, Ghayumi MA,
Haghshenas MR, Mojtahedi Z, Ghaderi A and Amani D: Increase of
regulatory T cells in metastatic stage and CTLA-4 over expression
in lymphocytes of patients with non-small cell lung cancer (NSCLC).
Lung Cancer. 77:306–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schneider T, Kimpfler S, Warth A, Schnabel
PA, Dienemann H, Schadendorf D, Hoffmann H and Umansky V: Foxp3(+)
regulatory T cells and natural killer cells distinctly infiltrate
primary tumors and draining lymph nodes in pulmonary
adenocarcinoma. J Thorac Oncol. 6:432–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Xiao Z, Gong J, Liu Z, Zhang M and
Zhang Z: A prognostic nomogram for lung adenocarcinoma based on
immune-infiltrating Treg-related genes: From bench to bedside.
Transl Lung Cancer Res. 10:167–182. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun S, Wang K, Guo D, Zheng H, Liu Y, Shen
H and Du J: Identification of the key DNA damage response genes for
predicting immunotherapy and chemotherapy efficacy in lung
adenocarcinoma based on bulk, single-cell RNA sequencing, and
spatial transcriptomics. Comput Biol Med. 171:1080782024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan Z, Wu S, Sang H, Li Q, Cheng S and Zhu
H: Identification of GPD1L as a potential prognosis biomarker and
associated with immune infiltrates in lung adenocarcinoma.
Mediators Inflamm. 2023:91622492023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu C, Wang Y, Dao Y, Wang S, Hou F, Yang
Z, Liu P, Lv J, Lv L, Li G, et al: Upregulation of CENPM
facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR
signaling pathway. Acta Biochim Biophys Sin (Shanghai). 54:99–112.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bai L, Li LH, Liang J and Li EX:
Prognostic significance of PTTG1 and its methylation in lung
adenocarcinoma. J Oncol. 2022:35074362022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Ma D, Gong Y, Wang F, Wu J and Wu
C: IL1R2 is a novel prognostic biomarker for lung adenocarcinoma.
Curr Mol Med. 24:620–629. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu S, Pan J, Pan Q, Zeng L, Liang R and Li
Y: Multi-omics profiling and experimental verification of tertiary
lymphoid structure-related genes: Molecular subgroups, immune
infiltration, and prognostic implications in lung adenocarcinoma.
Front Immunol. 15:14532202024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lei K, Tan B, Liang R, Lyu Y, Wang K, Wang
W, Wang K, Hu X, Wu D, Lin H and Wang M: Development and clinical
validation of a necroptosis-related gene signature for prediction
of prognosis and tumor immunity in lung adenocarcinoma. Am J Cancer
Res. 12:5160–5182. 2022.PubMed/NCBI
|
|
34
|
Liang J, Wang J, Azfer A, Song W, Tromp G,
Kolattukudy PE and Fu M: A novel CCCH-zinc finger protein family
regulates proinflammatory activation of macrophages. J Biol Chem.
283:6337–6346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang M, Vikis HG, Wang Y, Jia D, Wang D,
Bierut LJ, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, et
al: Identification of a novel tumor suppressor gene p34 on human
chromosome 6q25.1. Cancer Res. 67:93–99. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wawro M, Kochan J, Krzanik S, Jura J and
Kasza A: Intact NYN/PIN-Like domain is crucial for the degradation
of inflammation-related transcripts by ZC3H12D. J Cell Biochem.
118:487–498. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang B, Ji LL, Xu HL, Li XP, Zhou HG, Xiao
T, Li XH, Gao ZY, Li JZ, Zhang WD, et al: Zc3h12d, a novel of
hypomethylated and immune-related for prognostic marker of lung
adenocarcinoma. J Inflamm Res. 14:2389–2401. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen W, Guo Z, Wu J, Lin G, Chen S, Lin Q,
Yang J, Xu Y and Zeng Y: Identification of a ZC3H12D-regulated
competing endogenous RNA network for prognosis of lung
adenocarcinoma at single-cell level. BMC Cancer. 22:1152022.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gong W, Dai W, Wei H, Chen Y and Zheng Z:
ZC3H12D is a prognostic biomarker associated with immune cell
infiltration in lung adenocarcinoma. Transl Cancer Res.
9:6128–6142. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ranasinghe R and Eri R: pleiotropic immune
functions of chemokine receptor 6 in health and disease. Medicines
(Basel). 5:692018.PubMed/NCBI
|
|
41
|
Zhang CY, Qi Y, Li XN, Yang Y, Liu DL,
Zhao J, Zhu DY, Wu K, Zhou XD and Zhao S: The role of CCL20/CCR6
axis in recruiting Treg cells to tumor sites of NSCLC patients.
Biomed Pharmacother. 69:242–248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wei J, Yu W, Chen J, Huang G, Zhang L,
Chen Z, Hu M, Gong X and Du H: Single-cell and spatial analyses
reveal the association between gene expression of glutamine
synthetase with the immunosuppressive phenotype of APOE+CTSZ+TAM in
cancers. Mol Oncol. 17:611–628. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang J, Chen H, Zhao C, Li T, Zhang C, Ma
L, Su H, Ma L, Duan Z, Si Q, et al: PRTN3 promotes
IL33/Treg-mediated tumor immunosuppression by enhancing the M2
polarization of tumor-associated macrophages in lung
adenocarcinoma. Cancer Lett. 616:2175842025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang H, Ma J, Lu J, Wang Y, Zhang B, Zhang
H and Peng H: TMB is associated with the prognosis of egfr-mutated
non-small cell lung cancer in Xuanwei, China. Biomark Med.
18:1123–1133. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park SE, Park K, Lee E, Kim JY, Ahn JS, Im
YH, Lee C, Jung H, Cho SY, Park WY, et al: Clinical implication of
tumor mutational burden in patients with HER2-positive refractory
metastatic breast cancer. Oncoimmunology. 7:e14667682018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Goodman AM, Kato S, Bazhenova L, Patel SP,
Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R:
Tumor mutational burden as an independent predictor of response to
immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang C, Shen L, Qi F, Wang J and Luo J:
Multi-omics analysis of tumor mutation burden combined with immune
infiltrates in bladder urothelial carcinoma. J Cell Physiol.
235:3849–3863. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang JL, Dong YX, Di SY, Fan BS and Gong
TQ: Identification and experimental verification of an anoikis and
immune related signature in prognosis for lung adenocarcinoma.
Transl Cancer Res. 12:887–903. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xie Y, Chen H, Tian M, Wang Z, Wang L,
Zhang J, Wang X and Lian C: Integrating multi-omics and machine
learning survival frameworks to build a prognostic model based on
immune function and cell death patterns in a lung adenocarcinoma
cohort. Front Immunol. 15:14605472024. View Article : Google Scholar : PubMed/NCBI
|
